American Society of Gene & Cell Therapy

What American Society of Gene & Cell Therapy does

The American Society of Gene & Cell Therapy (ASGCT) is a 501(c)(3) nonprofit professional membership organization founded in 1996 and headquartered in Waukesha, Wisconsin, that serves as the principal community for the global cell and gene therapy (CGT) field. It unites researchers, scientists, clinicians, industry executives, trainees, patients, and advocates across more than 60 countries through tiered annual memberships ($85-$240), 35+ member-led scientific and standing committees, and the field's flagship Annual Meeting, which drew more than 7,000 attendees and 320+ exhibiting companies in 2026. ASGCT's product portfolio spans the Molecular Therapy journal family (four peer-reviewed titles published in partnership with Cell Press/Elsevier), the ASGCT Learning Center LMS platform, a 698+ item media library, a multi-show podcast network, and the newly launched CGTxchange — a jointly owned clearinghouse and marketplace with Orphan Therapeutics Accelerator that uses AI-enabled infrastructure to match shelved CGT programs in ultra-rare diseases with new sponsors. Revenue is generated through membership dues, event registration and corporate sponsorships (Bronze $5,000 to Gold $20,000+), journal publishing and advertising, and the newly established ASGCT Foundation (launched May 2026 as a wholly-owned charitable nonprofit), which raised more than $500,000 at its inaugural Momentum Gala.

In May 2026, ASGCT spun off the ASGCT Foundation to address funding gaps in research and patient access, and in January 2026 it entered the CGTxchange joint venture with OTXL, marking a strategic shift from purely informational and convening functions toward transactional deal-making for deprioritized therapy assets. ASGCT also operates as a field-defining policy voice, co-leading a 2025 joint statement with ISCT and ARM calling for a 10-year moratorium on heritable human genome editing, and maintaining institutional roles in FDA liaison meetings, the Alliance for a Stronger FDA, and the USP Convention.

Name

American Society of Gene & Cell Therapy

Legal name

American Society of Gene & Cell Therapy

Website

https://asgct.org

Company type

Private

Founded year

2000

Operating status

Operating

Headcount range

11–50 employees

Short description

ASGCT is a nonprofit professional membership organization serving the global cell and gene therapy community across 60+ countries through tiered memberships, the field's largest Annual Meeting (7,000+ attendees), the Molecular Therapy journal family, and the CGTxchange marketplace for shelved ultra-rare disease therapies.

Ownership category

akta.pro rank

Headquarters

HQ city

Milwaukee

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B and B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Others

Revenue model

1. Membership Dues: ASGCT generates revenue through annual membership dues across multiple tiers: Full Member ($200-$240), Early Career Member ($120), Trainee (Free), Allied Member ($85-$100). Members receive benefits including event discounts, journal access, and career center access.
2. Event Registration and Sponsorship: Revenue from Annual Meeting registration (7,000+ attendees, 320+ exhibiting companies), Policy Summit, Breakthroughs in Cell & Gene Therapy, and specialized workshops. Corporate sponsorship opportunities at multiple levels (Gold $20,000+, Silver $10,000+, Bronze $5,000+).
3. Publishing and Advertising: Revenue from publication fees in Molecular Therapy journals (with member discounts), advertising in newsletters, webinars, and podcasts, plus publication page charges.
4. Advertising and Exhibits: Year-round advertising opportunities in ASGCT e-newsletters, webinars, podcasts, and event exhibitor/tabletop placements for companies targeting the CGT community.

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels8 records

Core offering

ASGCT is a nonprofit professional membership organization that advances the cell and gene therapy field through tiered individual memberships, the Molecular Therapy journal family, flagship conferences (Annual Meeting, Policy Summit, Breakthroughs in Cell & Gene Therapy), continuing education via the ASGCT Learning Center, policy advocacy, and the CGTxchange marketplace for reactivating shelved therapies.

Differentiator

Problem solved

Functional benefit

Brands

• ASGCT Foundation: Charitable nonprofit organization dedicated to ensuring the life-changing potential of gene and cell therapy reaches every patient by addressing resource scarcity and systemic barriers
• CGTxchange
• Molecular Therapy Family of Journals
• ASGCT Podcast Network

Products and services

• ASGCT Membership Tiered annual professional membership for researchers, scientists, clinicians, executives, early-career professionals, trainees, patient advocates, and allied professionals in the cell and gene therapy field, providing access to journals, events, education, committees, and career resources.
• ASGCT Annual Meeting Annual flagship scientific conference bringing together CGT researchers, clinicians, and industry leaders for presentations, networking, exhibits, and sponsorship opportunities.
• ASGCT Policy Summit 2026 Annual policy and advocacy summit held in Washington D.C. for ASGCT members and non-members to engage on regulatory, research funding, and patient access policy issues affecting the CGT field.
• Breakthroughs in Cell & Gene Therapy 2026 Specialized conference on emerging breakthroughs in cell and gene therapy with both in-person and virtual registration options for researchers, clinicians, and industry professionals.
• GME Bootcamp in Cell and Gene Therapy Graduate medical education bootcamp preparing clinicians for integration of cell and gene therapies into patient care, hosted with Nationwide Children's Hospital.
• Safety, Translation, and Real-World Implementation of AAV and LNP Gene Therapies Program Specialty educational program co-hosted with CHOP's Clinical In Vivo Gene Therapy (CIGT) group covering safety, translation, and real-world implementation of AAV and LNP gene therapies.
• Molecular Therapy Journal Family Family of four peer-reviewed scientific journals (Molecular Therapy, Molecular Therapy Advances, Molecular Therapy Nucleic Acids, Molecular Therapy Oncology) published in partnership with Cell Press/Elsevier, serving as the authoritative scientific publications in CGT research.
• ASGCT Learning Center Learning management system (LMS) platform offering expert-led courses, content collections, professional development cafes, and 'Around the World' international sessions for CGT professionals.
• CGTxchange Marketplace Jointly owned clearinghouse and marketplace co-developed with Orphan Therapeutics Accelerator that connects shelved or deprioritized cell and gene therapy programs targeting ultra-rare diseases with new clinical sponsors and development partners.
• ASGCT Career Center

Quantifiable outcome

• $2 million in research funding awarded to ASGCT members
• +3 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature3 records

Partnerships

Eleven partnerships are on record, tiered minor and core.

• P4ML (UAE-based health innovation company)minorStrategic or Co-development Partner · 25 February 2026P4ML became a founding member of the Orphan Therapeutics Accelerator (OTXL), enhancing its role in accelerating access to therapies for ultra-rare diseases. The partnership supports expanding global development and access pathways amid regulatory changes, with P4ML leveraging its regional expertise and scientific partnerships to support the CGTxchange initiative.
• Orphan Therapeutics Accelerator (OTXL)coreStrategic or Co-development Partner · 7 January 2026ASGCT partnered with OTXL to establish CGTxchange, a jointly owned clearinghouse and marketplace for deprioritized cell and gene therapies targeting ultra-rare diseases. The platform uses OTXL's AI-enabled infrastructure to profile and risk-score shelved programs, matching them with new clinical sponsors and development partners. ASGCT and OTXL co-own the platform, which addresses a growing challenge where policy and economic shifts have led biopharma sponsors to halt development of clinically beneficial CGTs.
• Bespoke Gene Therapy Consortium (BGTC)minorStrategic or Co-development PartnerASGCT is a member of the Accelerating Medicines Partnership - Bespoke Gene Therapy Consortium, working with NCATS/NIH and other partners to advance gene therapy development.
• Alliance for a Stronger FDAminorStrategic or Co-development PartnerASGCT is a member of the Alliance for a Stronger FDA, advocating for robust federal appropriations for FDA.
• United States Pharmacopeia (USP) ConventionminorStrategic or Co-development PartnerASGCT is a member of the USP Convention, contributing to standards development for cell and gene therapies.
• International Society for Cell & Gene Therapy (ISCT)minorStrategic or Co-development PartnerASGCT co-led a 2025 statement with ISCT and Alliance for Regenerative Medicine calling for a 10-year moratorium on heritable human genome editing.
• Alliance for Regenerative Medicine (ARM)minorStrategic or Co-development PartnerASGCT co-led a 2025 statement with ISCT and ARM calling for a 10-year moratorium on heritable human genome editing.
• Children's Hospital of Philadelphia (CHOP) - Clinical In Vivo Gene Therapy GroupcoreStrategic or Co-development PartnerASGCT partners with CHOP's Clinical In Vivo Gene Therapy (CIGT) group to present the Safety, Translation, and Real-World Implementation of AAV and LNP Gene Therapies program. CHOP provides clinical expertise and hosting at the Morgan Center for Research and Innovation.
• Nationwide Children's HospitalcoreStrategic or Co-development PartnerASGCT partners with Nationwide Children's Hospital in Columbus, OH to host the Graduate Medical Education Bootcamp in Cell and Gene Therapy, designed to prepare next-generation clinicians for CGT integration into patient care.
• Medical College of WisconsinminorStrategic or Co-development PartnerASGCT acknowledges the support of the Medical College of Wisconsin, which assisted in facilitating and capturing photography used throughout the Society's marketing and promotional materials.
• Cell Press / ElseviercoreStrategic or Co-development PartnerASGCT is the scientific home of the Molecular Therapy journal family, published in partnership with Cell Press/Elsevier. The journals include Molecular Therapy, Molecular Therapy Advances, Molecular Therapy Nucleic Acids, and Molecular Therapy Oncology.

Scale indicators7 records

Recent moves8 records

Expansion highlights6 records

Broad incumbents

• American Society of Hematology (ASH): ASH is a much larger US-based hematology professional society whose members include many CGT researchers/clinicians (e.g., bone marrow transplant) and which offers an adjacent Annual Meeting with overlapping scientific and corporate audiences.
• Biotechnology Innovation Organization (BIO): BIO is a large biotech trade association with broad policy advocacy, industry conventions (e.g., BIO International Convention), and corporate sponsorship reach that competes with ASGCT for biotech/pharma engagement and influence.
• American Association for Cancer Research (AACR): AACR is the largest US oncology research society publishing multiple high-impact journals and hosting a large annual meeting; it serves an overlapping CGT-in-oncology membership and competes for biotech sponsorship dollars.
• American Society of Clinical Oncology (ASCO): ASCO is the dominant professional society for clinical oncology, including cellular therapy and CAR-T—publishing flagship journals, running the largest oncology meeting, and competing for biotech ad/sponsorship budgets in CGT-adjacent areas.
• American Association of Immunologists (AAI): AAI is a long-standing immunology professional society publishing The Journal of Immunology with comparable membership, journals, and meeting model—directly relevant to immunologically-focused CGT research and trainees.

Direct peers

• International Society for Cell & Gene Therapy (ISCT): ISCT is the most direct peer—a global professional society focused on cell and gene therapy translation, with overlapping membership, parallel annual meeting, and co-signed policy positions with ASGCT (e.g., 2025 heritable genome editing moratorium statement).
• Alliance for Regenerative Medicine (ARM): ARM is an industry-led trade association advancing regenerative medicine and cell/gene therapies globally; it competes for biotech/pharma sponsorships and policy influence and has co-led advocacy positions with ASGCT.
• National Organization for Rare Disorders (NORD): NORD is a US patient advocacy organization for rare diseases and a relevant peer given ASGCT's patient advocate membership track and rare disease policy focus (e.g., ultra-rare CGTs via CGTxchange).

Emerging players

• Society for Immunotherapy of Cancer (SITC): SITC is a focused professional society for tumor immunology and cellular therapy, with an annual meeting and member programs adjacent to CGT oncology—competing for scientific publications, sponsorship, and meeting attendance among immuno-oncology researchers.

Regional players

• European Society of Gene and Cell Therapy (ESGCT): ESGCT is the European counterpart professional society in CGT, hosting its own annual congress and serving European researchers/clinicians—geographically adjacent but covering the same scientific domain as ASGCT.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/asgctherapy
• YouTubeyoutube.com/user/ASGCT
• Facebookfacebook.com/American-Society-of-Gene-Cell-Ther
• LinkedInlinkedin.com/company/asgct

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Subsidiaries1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about American Society of Gene & Cell Therapy